Inflammation, Skin Patents (Class 514/886)

Cross-Reference Art Collections

Topical treatment (Class 514/887)
  • Patent number: 9035030
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: May 19, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 8993640
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: March 31, 2015
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Xiaofeng Liu, Andrea Decker
  • Patent number: 8945545
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: February 3, 2015
    Assignee: AbbVie Inc.
    Inventors: Joaquin Mario Valdes, Susan K. Paulson
  • Patent number: 8916525
    Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: December 23, 2014
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, The Catholic University of Korea
    Inventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Jin Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
  • Patent number: 8906865
    Abstract: This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs, or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction or levels of inflammatory mediators.
    Type: Grant
    Filed: March 25, 2008
    Date of Patent: December 9, 2014
    Assignee: ISIS Innovation Limited
    Inventors: David R. Greaves, Andreas Russ, Jenna L. Cash
  • Patent number: 8865174
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 8853264
    Abstract: The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a method for preventing or treating an inflammatory disease, comprising administering to a subject in need thereof an effective amount of macelignan represented by Chemical Formula I or a pharmaceutically acceptable salt thereof. The lignan compound has the effect of inhibiting inflammatory reactions by inhibiting the production or expression of inflammation mediators NO, iNOS, PGE2, COX-2 and TNF-? and by treating or preventing inflammatory disease in vivo. Accordingly, the lignan compound or a Myristica fragrans extract will be highly useful for the treatment or prevention of an inflammatory disease.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: October 7, 2014
    Assignees: Newtree Industry Co., Ltd.
    Inventors: Jae-Kwan Hwang, Do-Un Kim, Jae-Youn Chung, Hee-Chul Chung, Kyu-Lee Han
  • Patent number: 8784780
    Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: July 22, 2014
    Assignee: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Lisa Chin, Poonam S. Hirani
  • Patent number: 8734783
    Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: May 27, 2014
    Assignee: Probiotical S.p.A.
    Inventors: Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna, Lorenzo Drago
  • Patent number: 8691285
    Abstract: Methods of using a non-irritant, low pH acidic composition to destroy undesirable microorganisms are described. The methods may be used on food products, food processing equipment, and in aqueous solutions.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: April 8, 2014
    Assignee: CMS Innovative Technologies, Inc.
    Inventors: Barry Cummins, David Creasey
  • Patent number: 8673281
    Abstract: A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: March 18, 2014
    Assignee: BioCis Pharma Oy
    Inventors: Lasse Leino, Jarmo Laihia
  • Patent number: 8642646
    Abstract: The present invention relates to a method and composition for treating acne using lignan compounds represented by Formula 1. More particularly, the invention relates to an antibacterial composition against acne-causing bacteria, containing lignan compounds represented by Formula 1, as well as a method for treating acne using the same. The lignan compounds represented by Formula 1 are excellent not only in the antibacterial activity of inhibiting the growth of acne-causing bacteria, but also in thermal stability. Accordingly, the lignan compounds may be useful as antibacterial agents against the acne-causing bacteria, and acne treatment agents.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: February 4, 2014
    Assignees: New Tree Industry Co., Ltd.
    Inventors: Jae-Kwan Hwang, Jae-Youn Chung, Hee-Chul Chung, Kyung-Min Park
  • Patent number: 8586564
    Abstract: The present invention describes compositions and methods for synthetic analogues and derivatives of ?-glycolipids. These analogues and derivatives may be used for the treatment, amelioration or prevention of a pathological disorder. They may also be used for the modulation of the Th1/Th2 cell balance toward an anti-inflammatory or pro-inflammatory response, resulting in the treatment, amelioration or prevention of immune-related disorders.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: November 19, 2013
    Assignee: Enzo Therapeutics, Inc.
    Inventor: Yaron Ilan
  • Patent number: 8580315
    Abstract: The present invention relates to anti-inflammatory activity of eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to eggshell membrane compositions exhibiting anti-inflammatory activity as measured by effects on down-regulating pro-inflammatory plasma antigens in mammals that had orally ingested such compositions. This information supports the potential benefits from administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations to reduce pain and inflammation associated with arthritis and other inflammatory conditions.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: November 12, 2013
    Assignee: ESM Technologies, LLC
    Inventors: Dale Paul DeVore, Frank Daniel Long
  • Patent number: 8575089
    Abstract: The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating the inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: November 5, 2013
    Assignee: University-Industry Cooperation Group of Kyung Hee
    Inventors: Young Sook Son, Hyun Sook Hong, Do Yeon Kim, Eun Kyung Lee
  • Patent number: 8557846
    Abstract: The methods disclosed herein relate to the treatment of dermal disorders, such as for example atopic dermatitis, in dogs, by administering a therapeutically effective amount of racemic norketotifen. Co-administrations with steroids or immunosuppressant drugs are described.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: October 15, 2013
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
  • Patent number: 8557239
    Abstract: The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: October 15, 2013
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Joaquin Mario Valdes, Elliot K. Chartash, William T. Barchuk, Susan K. Paulson, Kenneth B. Gordon, Walid M. Awni, Yanjun Bao, William G. Glass, Yihua Gu, Tom C. Harris, Martin Kaul, Parvez M. Mulani, Peter Noertersheuser, Martin M. Okun
  • Patent number: 8529970
    Abstract: Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. Properties that are sought in traditional saponification of natural oils are a result of low levels of unsaponifiables. These properties include high levels of aqueous surfactant activity, water-solubility or ready water-dispersability, activity as foaming agents, and the like. An objective of traditional saponification processes is to increase the water-solubility and surfactant activity of naturally occurring materials. It has been found that the application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6 weight percent of the material), produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6 weight percent of unsaponifiables.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: September 10, 2013
    Assignee: International Flora Technologies, Ltd.
    Inventors: James H. Brown, Lee Roy Copeland, Robert Kleiman, Melanie K. Cummings, Sambasivarao Koritala
  • Patent number: 8466128
    Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for malting and using the same.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: June 18, 2013
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventor: Robert Lewis
  • Patent number: 8435540
    Abstract: The present invention concerns methods and compositions for PEGylated complexes of defined stoichiometry and structure. Preferably, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and a PEG moiety to an AD sequence, allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. Alternatively, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-?2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: May 7, 2013
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Patent number: 8414887
    Abstract: The present invention relates to compositions and methods for use in the treatment of conditions such as septicaemia and septic shock. The invention further provides compositions and methods for the suppression Toll-like Receptor 4 mediated activation of the immune system. The invention further provides screening assays to identify compounds which have utility in the foregoing compositions and methods.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: April 9, 2013
    Assignee: Opsona Therapeutics Limited
    Inventors: Luke O'Neill, Susan Carpenter, Aisling Dunne
  • Patent number: 8377679
    Abstract: The present invention pertains to the use of probiotics for the preparation of a carrier for balancing the skin's immune function. In particular, the present invention pertains to the use of probiotic micro-organisms for balancing the skin's immune function under stress conditions, such as a exposure to ultraviolet radiation, specifically for enhancing the skin's immune activity and reducing the tendency to develop allergic reactions under such conditions.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: February 19, 2013
    Assignee: Nestec S.A.
    Inventors: Markus Baur, Lionel Breton, Francois Couzy, Audrey Gueniche
  • Patent number: 8349793
    Abstract: The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: January 8, 2013
    Assignee: Heal0r, Ltd.
    Inventors: Liora Braiman-Wiksman, Tamar Tennenbaum, Yuvai Sagiv, Marina Gartsbein, Ephraim Brener, Moshe Ben-Hamo, Liat Hammer
  • Patent number: 8313738
    Abstract: A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: November 20, 2012
    Assignee: BioCis Pharma Oy
    Inventors: Lasse Leino, Jarmo Laihia
  • Patent number: 8236323
    Abstract: The present invention relates generally to the fields of pharmacology, and particularly to a method for treating inflammation, particularly inflammation of the respiratory system. The invention provides a method to reduce or ameliorate inflammation, by administering an effective amount of a protein factor originally isolated from thymic tissue, and referred to as T4 immune stimulating factor (TISF).
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: August 7, 2012
    Assignee: S-Cell Biosciences, Inc.
    Inventor: Terry Raymond Beardsley
  • Patent number: 8178092
    Abstract: The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: May 15, 2012
    Assignee: Abbott Laboratories
    Inventors: Joaquin Mario Valdes, Susan K. Paulson
  • Patent number: 8153592
    Abstract: This description provides methods and materials related to modulating Toll-like receptor activity. For example, methods and materials for increasing or decreasing the responsiveness of a TLR4 polypeptide are provided.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: April 10, 2012
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Jeffrey L. Platt, Gregory J. Brunn
  • Patent number: 8129383
    Abstract: There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 6, 2012
    Assignee: Aminopterin LLC
    Inventors: John Zebala, Barton A. Kamen
  • Patent number: 8106098
    Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: January 31, 2012
    Assignee: The General Hospital Corporation
    Inventor: Mikhail I. Papisov
  • Patent number: 8025651
    Abstract: A urinary anti-backflow device is provided which prevents urine from flowing back into the patient's bladder from a urine collection bag. The device comprises a flow tube having an upstream section connectable to an external urinary device secured to a patient and a downstream section connectable to a urine collection bag, a rod within the flow tube, and a stopper which moves along the rod between the downstream and upstream ends of the flow tube. When the upstream section of the flow tube is elevated relative to the downstream section, urine from the patient is free to flow through the flow tube. When the downstream section of the flow tube is elevated relative to the upstream section, urine forces the stopper against the upstream section to prevent backflow.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: September 27, 2011
    Inventor: Carl Hart
  • Patent number: 8017122
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: September 13, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Patent number: 8012511
    Abstract: A composition of matter and the method of making that provide a low pH acidic composition that is useful for destroying microorganisms that are undesirable and useful for destroying or reducing melanoma on human skin. The composition and method include a strong, low pH acid combined with distilled water and urea or an ammonium compound, such as ammonium sulfate or other metallic sulfates, including but not limited to, sodium sulfate, magnesium sulfate, zinc sulfate, manganese sulfate, and copper sulfate, under at least 15 psi pressure in pressurized container, all of which is heated to approximately 800° F. or more for at least 3 hours. The final cooled mixture is stabilized with 10 to 15 percent of the original mixture. The resultant composition is useful for preserving food, such as fresh fish, and for skin treatment of melanoma and as bactericides, fungicides, or viricides.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: September 6, 2011
    Assignee: Contact Marketing Solutions, LLC
    Inventors: Barry W. Cummins, David H. Creasey
  • Patent number: 7964220
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 21, 2011
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7955623
    Abstract: The present invention refers to a pharmaceutical preparation for treating inflammatory diseases and microbial infections comprising a pharmaceutically effective amount of ozone and at least one monomeric amino acid having an oxidation-sensitive side chain, or at least one ozonized monomeric amino acid having an oxidation-sensitive side chain. Also described is the use of a preparation as described before for providing a medicament for treating inflammatory diseases, microbial infections and for immune modulation. The pharmaceutical preparation according to the invention is particularly useful in the treatment of oral inflammations.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: June 7, 2011
    Inventors: Karin Christine Huth, Korbinian Brand
  • Patent number: 7786042
    Abstract: The invention relates to a novel use of fluridone—compound known per se and used as an aquatic erbicide—in the medical field, in particular as an active compound for preparing a medicament having anti-inflammatory activity. Pharmaceutical compositions comprising fluridone as an active compound and pharmaceutically acceptable carriers and/or diluents are also disclosed. Finally, there is disclosed the pro-inflammatory activity of abscisic acid (ABA), a plant hormone which is also found in mammal serum and against which fluridone acts an inhibitor.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: August 31, 2010
    Assignee: Universita' Degli Studi Di Genova
    Inventors: Elena Zocchi, Lucrezia Guida, Santina Bruzzone, Sonia Scarfi′, Mirko Magnone, Giovanna Basile, Umberto Benatti, Antonio De Flora, Iliana Moreschi, Luisa Franco, Annalisa Salis
  • Patent number: 7786097
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: August 31, 2010
    Assignee: Pfizer Inc.
    Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A Decresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
  • Patent number: 7741292
    Abstract: A method of inhibiting the emigration of cells from the intravascular compartment into tissues (or through any membrane limiting any body compartment from another) by confronting the cells with an agonist specific for receptors involved with migration of said cells via a receptor thereby making the cell unresponsive to further activation.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: June 22, 2010
    Assignee: IPF Pharmaceuticals GmbH
    Inventors: Ulf Forssmann, Jörn Elsner, Sylvia Escher, Nikolaj Spodsberg
  • Patent number: 7700077
    Abstract: The invention concerns the use for treating and cleaning the eye and its appendages of aqueous ionic solutions obtained from sea water whereof the ionic composition is qualitatively that of sea water and quantitatively such that their pH ranges between 4 and 9, preferably between 7 and 8 and their osmolality ranges between 150 and 700, preferably between 250 and 350 mOsm/kg.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: April 20, 2010
    Assignee: Laboratories de la Mer
    Inventors: Jean-Claude Yvin, Benedicte Marie Dominique Halley, Didier Leroy
  • Patent number: 7666914
    Abstract: Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment which comprise applying the various disclosed combinations of agents to the patient's skin.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: February 23, 2010
    Inventors: David M. Richlin, George R. Doherty
  • Patent number: 7604797
    Abstract: The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof; and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: October 20, 2009
    Assignee: BioMechanisms Inc.
    Inventor: Terry Lee Hicks
  • Patent number: 7575764
    Abstract: Disclosed are topical compositions comprising extracts of Hypsizygus ulmarius in amounts that are effective to influence LTB4-mediated chemotaxis and/or IL-1? mediated adhesion of polymorphonuclear leukocytes. The hypsizygus ulmarius extract may be used alone or in combination with secondary anti-inflammatory and skin active agents, such as other mushroom and/or natural extracts. The secondary anti-inflammatory agents may or may not function by antagonizing LTB4-mediated chemotaxis and IL-1? mediated adhesion. The extract may be incorporated into a cosmetically acceptable vehicle. The present invention includes methods of treating skin inflammation by applying to inflamed skin, anti-inflammatory effective amounts of Hypsizygus ulmarius extract in a defined treatment regimen.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: August 18, 2009
    Assignee: ELC Management LLC
    Inventors: Chia Chen, Andrew Weil, Paul Stamets
  • Patent number: 7556818
    Abstract: A composition and method of applying to skin which has psoriasis a gel that contains curcumin and/or curcuminoids. Prior to applying of the gel to the skin, the affected layer is soaked in one-hundred percent alcohol. The alcohol functions to dissolve the curcumin and/or curcuminoids with the alcohol not only comprising a solvent but functions as a carrier to cause the freshly dissolved (nascent) curcumin to penetrate through the stratum corneum layer of the skin and into the epithelial layer of the skin.
    Type: Grant
    Filed: July 3, 2004
    Date of Patent: July 7, 2009
    Inventor: Madalene C. Y. Heng
  • Patent number: 7534438
    Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: May 19, 2009
    Assignee: National Jewish Health
    Inventor: Carl W. White
  • Patent number: 7473432
    Abstract: The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: January 6, 2009
    Assignee: Idea AG
    Inventors: Gregor Cevc, Ulrich Vierl
  • Patent number: 7431953
    Abstract: It is an object of the present invention to provide anti-allergic agents, skin creams, dermatitis-blocking agents, pollinosis-alleviating agents, and bath agents that serve as antipruritics derived from natural products and that prevent, alleviate and treat various itches felt on the skin. The present invention relates to anti-allergic agents, skin creams, dermatitis-blocking agents, pollinosis-alleviating agents, and bath agents comprising Purpuricenus temminckii frass as an ingredient.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: October 7, 2008
    Assignee: Nihon University
    Inventors: Seishiro Mochizuki, Hirotaka Kishida, Toshinori Ishikawa, Toshihiro Akihisa, Yoshihiro Suzuki
  • Patent number: 7425332
    Abstract: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: September 16, 2008
    Assignees: Yeda Research and Development Co., Ltd., President and Fellows of Harvard University
    Inventors: Michael Sela, Masha Fridkis-Hareli, Jack L. Strominger, Rina Aharoni, Dvora Teitelbaum, Ruth Arnon
  • Patent number: 7404949
    Abstract: A method and composition is provided for managing in-grown hair which involves applying to those areas malonic acid or a salt thereof in a carrier. The method and composition allows for comfortable shaving of skin by minimizing the problem of in-grown hair.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: July 29, 2008
    Assignee: Unilever Home & Personal Care USA, division of Conopco, Inc.
    Inventors: Joseph Raymond Faryniarz, Michael Charles Cheney, Anthony William Johnson
  • Patent number: 7390796
    Abstract: Compounds are disclosed of the formula in which R3 is C8 to C24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by local or topical administration.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: June 24, 2008
    Assignee: Sepracor Inc.
    Inventors: Mark G. Currie, Steven Jones, Charles M. Zepp
  • Patent number: RE41109
    Abstract: A composition of matter and the method of making that provides a low pH acidic composition that is useful for destroying microorganisms that are undesirable and useful for destroying or reducing melanomas on human skin. The composition and method include sulfuric acid combined with distilled water and ammonium sulfate under at least 15 psi pressure in a pressurized container, all of which is heated to approximately 800° F. or more for at least 3 hours. The final cooled mixture is stabilized with 10 percent of the original mixture. The resultant composition is useful for preserving food, such as fresh fish, and for skin treatment of melanoma and as bactericides, fungicides, or viricides.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: February 9, 2010
    Assignee: Phitex, L.L.L.P.
    Inventor: Barry W. Cummins